Smart Multifunctional silica-based Nanoparticles for Targeted Therapy

Informacje na temat projektu

NanoSil4Cancer

Identyfikator umowy o grant: 736632

DOI

10.3030/736632

Projekt został zamknięty

Data podpisania przez KE 11 Lipca 2016

Data rozpoczęcia 1 Września 2016

Data zakończenia 28 Lutego 2017

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

NANOSILICAL DEVICES SRL
Italy

Periodic Reporting for period 1 - NanoSil4Cancer (Smart Multifunctional silica-based Nanoparticles for Targeted Therapy)

Okres sprawozdawczy: 2016-09-01 do 2017-02-28

Podsumowanie kontekstu i ogólnych celów projektu

Anticancer drugs are administered at high doses, killing the diseased cells, but also showing severe toxic effects on the healthy ones. Unsustainable side effects and lack of therapeutic efficacy lead to patients non-adherence to the therapy and high medical costs.
NanoSil4Cancer is an innovative biocompatible device able to administer cancer therapies with low drug doses, high therapeutic efficacy and reduced side effects. Therapeutic efficacy increases because drugs are directly administered to cancer cells. NanoSiliCal reformulates known, approved drugs, through its proprietary drug delivery technology and creates new medications with improved clinical and economic benefits for patients and healthcare stakeholders.

The objectives for the Phase I study included (1) the analysis of customer needs, (2) analysis of the market size, (3) partner search and B2B strategy development, (4) the refinement of the business model and go-to-market strategy, (5) risk assessment, (6) elaboration of a long term perspective financial plan.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

NanoSiliCal conducted interviews with experts from the field and complemented the information with internet and database searches.
The epidemiological analysis provides evidence of the growth of cancer incidence and the need of treatments of higher efficacy and safety.
The economic impact of NanoSiliCal MSN prototypes development, analyzed on the base of financial projections, shows a highly competitive formulation development cost structure.
Several other drugs presenting features compatible with MSN have been identified, for developing NanoSilical pipeline.
Industrial stakeholders helped NanoSilical to define the company strategic plan to obtain marketing authorization and market penetration.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Based on the results of the phase I project, NanoSiliCal decided to develop two prototypes of nanoparticles loaded with two different drugs. NanoSiliCal planned to pursue completion of the clinical trial for one of the two prototypes, while progressing with the preclinical study for the other.

After the clinical trial stage, two different possible scenarios are foreseen, depending on the business agreement with present and possible future investors/partners : or the direct marketing of the product, or exclusive license of the prototype to a pharmaceutical company.
NanoSil4Cancer addresses cancer patient needs, developing an innovative technology for targeted drug delivery systems that can reduce side effects, thus increasing patients quality of life.

NanoSiliCal image